Mounjaro vs Wegovy: Which Works Better for Weight Loss in 2026?

Search “Mounjaro vs Wegovy” and you get before-and-after photos and one-line verdicts. Most miss the first problem: the two brands were never approved for the same job. Mounjaro is a type 2 diabetes drug. Wegovy is a weight-loss drug. Pitting them against each other is a category error — one that has spilled from TikTok into exam rooms.

The real weight-loss face-off is Wegovy against Mounjaro’s twin, Zepbound — the same molecule, a different label. And in 2026, that contest shifted: a new high-dose Wegovy quietly closed a gap that looked decisive a year ago.

Quick Answer

The only head-to-head trial gave tirzepatide (the active drug in Zepbound and Mounjaro) a clear win over semaglutide (Wegovy): 20.2% average body-weight loss vs 13.7% over 72 weeks. Two 2026 developments complicate that verdict. First, Wegovy HD — a higher-dose semaglutide approved in March 2026 — reached 20.7% in its own trial, though no study has compared it directly against tirzepatide. Second, Wegovy has proven heart-attack and stroke protection that tirzepatide hasn’t matched yet. “Better” depends on what you measure.

First, Fix the Matchup: Which Brand Does What

| Brand | Active ingredient | FDA-approved for | |---|---|---| | Mounjaro | tirzepatide | Type 2 diabetes (approved May 2022) | | Zepbound | tirzepatide | Weight management; obstructive sleep apnea (approved November 2023) | | Wegovy | semaglutide 2.4 mg | Weight loss; cardiovascular risk reduction; MASH, an advanced form of fatty liver disease (approved June 2021) | | Wegovy HD | semaglutide 7.2 mg | Weight loss (approved March 19, 2026) |

A doctor can legally prescribe Mounjaro off-label — meaning for a use the FDA has not approved — and some do. But it carries no weight-loss indication, and insurance coverage often hinges on that distinction.

How the Two Drugs Actually Differ

Both drugs mimic GLP-1 (glucagon-like peptide-1), a hormone your gut releases after you eat. It tells your brain you’re full, slows how fast your stomach empties, and prompts the pancreas to release insulin when blood sugar rises. Semaglutide works through this one receptor — which is why people simply call it a GLP-1 drug.

Tirzepatide adds a second target: GIP (glucose-dependent insulinotropic polypeptide), another gut hormone involved in insulin release and fat metabolism. It was the first drug to activate both receptors at once. That dual action is the leading explanation for its stronger trial results — though scientists still debate how much the GIP component actually contributes. The clinical edge is clear; the precise “why” is not.

What the Head-to-Head Evidence Shows

The SURMOUNT-5 trial settled the direct comparison. Researchers randomized 751 adults with obesity (without diabetes) to the maximum tolerated dose of either drug for 72 weeks:

Real-world records agree. A 2024 JAMA Internal Medicine study of electronic health records found 42.3% of tirzepatide users hit 15% weight loss at one year, versus 18.1% on semaglutide. That’s observational data, not a trial — but it points the same way.

Then 2026 delivered a curveball. The STEP UP trial showed Wegovy HD (7.2 mg) produced 20.7% average loss, rising to 27.7% among early responders. Those numbers sit right next to tirzepatide’s 20.2% — but they came from different trials with different populations. Cross-trial math is how marketing departments lie to you. Until high-dose semaglutide and tirzepatide face off in the same study, nobody honestly knows which wins.

Where Wegovy Still Leads: Your Heart

Weight loss isn’t the whole story. In the SELECT trial of 17,604 people with obesity and existing heart disease, semaglutide cut the risk of heart attack, stroke, or cardiovascular death by 20%. Wegovy holds an FDA approval for that indication. Tirzepatide doesn’t — its cardiovascular outcomes trial is still running.

A 2025 real-world analysis went further, linking Wegovy to a 57% greater reduction in heart events than tirzepatide — but that was observational data from a drugmaker’s press release, not a randomized trial. Treat it as a signal, not a verdict.

What They Cost in 2026

US list prices, roughly, per month:

Medicare’s GLP-1 Bridge program began July 1, 2026, offering coverage around $50/month for eligible Part D enrollees through 2027. Details and savings options are in our Wegovy cost and savings guide.

What the Internet Gets Wrong

“Mounjaro is a weight-loss drug.” No — that’s Zepbound. Same molecule, different approval, different insurance reality.

“20.7% beats 20.2%, so Wegovy HD wins.” Different trials, different populations. That comparison is numerology, not science.

Celebrity transformations as evidence. Rapid weight loss itself causes facial fat loss, regardless of method. A dramatic photo tells you nothing about which drug, if any, was involved. And “Ozempic face” is a media label, not a diagnosis.

Compounded versions are the same thing. They’re not. Compounded semaglutide and tirzepatide are not FDA-approved products and carry none of the trial evidence above.

Questions Worth Bringing to Your Doctor

Seek urgent medical care for severe or persistent abdominal pain (which can signal pancreatitis — a dangerously inflamed pancreas), vomiting that won’t stop, swelling or trouble breathing that suggests an allergic reaction, or a new lump in your neck. These drugs carry a warning about thyroid tumors seen in rodent studies; whether that risk applies to humans is unknown, but a neck lump is never a watch-at-home symptom.

There is no universal “best GLP-1” — the honest answer depends on your heart, your labs, and your coverage. We compare the full field in which GLP-1 is best for weight loss, and you can browse individual medication profiles for deeper detail.

Which Wins Depends on Your Heart and Your History

On weight-loss numbers alone, tirzepatide (Zepbound) holds the only head-to-head trial win, and real-world data backs it up. But Wegovy HD has narrowed the gap to within measurement error — pending a direct trial — and standard Wegovy remains the only one of the two with proven protection against heart attack and stroke. The right question was never “Mounjaro or Wegovy.” It’s which molecule, at which dose, for which patient. That’s a conversation for a prescriber who knows your history, not a comment section.

Frequently Asked Questions

Is Mounjaro or Wegovy better for weight loss? Neither is the clean comparison. For weight loss, the real matchup is Zepbound (tirzepatide) vs Wegovy (semaglutide). Tirzepatide won the only direct trial, 20.2% to 13.7% average loss.

Can I take Mounjaro for weight loss without diabetes? Doctors sometimes prescribe it off-label, but it’s not FDA-approved for weight loss, and insurers frequently refuse coverage for that use. Zepbound is the approved tirzepatide brand.

What’s the difference between Mounjaro and Zepbound? The molecule is identical. The difference is the FDA-approved use, the branding, and often what your insurance will pay for.

Is Wegovy HD stronger than Zepbound? Unknown. Wegovy HD hit 20.7% average loss in its own trial versus tirzepatide’s 20.2% in another — but no study has pitted them against each other directly.

Which is safer, semaglutide or tirzepatide? Both share similar gastrointestinal side-effect profiles in trials. Neither has shown a clear overall safety advantage; the right choice depends on your medical history.

Should I switch from Wegovy to tirzepatide? That’s a decision for your prescriber. Weight-loss response, side effects, heart health, and cost all factor in — and stopping or switching any GLP-1 medication should be medically supervised.

This article is for general education only and does not replace medical advice from a licensed healthcare professional. Never start, stop, or change a medication based on what you read online.